Hualan Biological Engineering Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Hualan Biological Engineering kazanç ve gelirin sırasıyla yıllık 18% ve 17.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 19.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.0%

Kazanç büyüme oranı

19.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.3%
Gelir büyüme oranı	17.5%
Gelecekteki özkaynak getirisi	12.5%
Analist kapsamı	Good
Son güncelleme	25 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Nov 18

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Oct 07

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Aug 22

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 26

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Jun 09

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Jun 07

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

May 21

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Feb 27

Kazanç ve Gelir Büyüme Tahminleri

SZSE:002007 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	7,213	1,961	2,324	1,826	9
12/31/2025	6,190	1,691	2,476	1,642	11
12/31/2024	5,136	1,362	1,627	2,130	7
9/30/2024	4,920	1,338	436	1,113	N/A
6/30/2024	5,409	1,395	256	900	N/A
3/31/2024	5,249	1,392	346	1,027	N/A
12/31/2023	5,342	1,482	592	1,346	N/A
9/30/2023	4,828	1,243	807	1,538	N/A
6/30/2023	3,753	1,020	1,099	1,713	N/A
3/31/2023	4,757	1,194	835	1,268	N/A
1/1/2023	4,517	1,076	563	957	N/A
9/30/2022	4,677	1,139	136	662	N/A
6/30/2022	5,497	1,425	54	704	N/A
3/31/2022	4,453	1,277	474	1,225	N/A
1/1/2022	4,436	1,299	621	1,432	N/A
9/30/2021	5,311	1,709	1,016	1,642	N/A
6/30/2021	4,925	1,559	907	1,594	N/A
3/31/2021	4,969	1,621	764	1,495	N/A
12/31/2020	5,023	1,613	704	1,325	N/A
9/30/2020	4,134	1,284	608	1,166	N/A
6/30/2020	3,684	1,288	902	1,295	N/A
3/31/2020	3,682	1,271	953	1,271	N/A
12/31/2019	3,700	1,283	1,090	1,363	N/A
9/30/2019	3,819	1,344	1,088	1,334	N/A
6/30/2019	3,418	1,194	1,214	1,451	N/A
3/31/2019	3,351	1,192	1,255	1,440	N/A
12/31/2018	3,217	1,140	1,109	1,293	N/A
9/30/2018	2,738	961	746	864	N/A
6/30/2018	2,556	843	N/A	590	N/A
3/31/2018	2,392	773	N/A	308	N/A
12/31/2017	2,368	821	N/A	177	N/A
9/30/2017	2,195	792	N/A	146	N/A
6/30/2017	2,091	801	N/A	120	N/A
3/31/2017	2,061	843	N/A	203	N/A
12/31/2016	1,935	780	N/A	330	N/A
9/30/2016	1,767	737	N/A	443	N/A
6/30/2016	1,671	690	N/A	585	N/A
3/31/2016	1,585	632	N/A	549	N/A
12/31/2015	1,472	589	N/A	549	N/A
9/30/2015	1,386	575	N/A	501	N/A
6/30/2015	1,372	563	N/A	429	N/A
3/31/2015	1,263	514	N/A	429	N/A
12/31/2014	1,243	538	N/A	497	N/A
9/30/2014	1,237	547	N/A	541	N/A
6/30/2014	1,141	530	N/A	501	N/A
3/31/2014	1,104	519	N/A	503	N/A
12/31/2013	1,118	475	N/A	511	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 002007 'nin tahmini kazanç büyümesi (yıllık 18% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 002007 şirketinin kazançlarının (yıllık 18% ) CN pazarından (yıllık 26.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 002007 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 002007 şirketinin gelirinin (yıllık 17.5% ) CN pazarından (yıllık 13.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 002007 şirketinin gelirinin (yıllık 17.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 002007 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.5 %).

Hualan Biological Engineering Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 7.4% to CN¥22.68

Price target increased to CN¥26.17

Price target decreased to CN¥27.73

Consensus revenue estimates increase by 11%

Price target decreased to CN¥33.57

Price target decreased to CN¥33.57

Recent updates

Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate

Hualan Biological Engineering Inc. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 16%

Price target decreased by 7.4% to CN¥22.68

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Dividend of CN¥0.30 announced

Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥26.17

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021)

Investor sentiment improved over the past week

Hualan Biological Engineering Inc. Announces Final Cash Dividend on A Shares for 2021, Payable on 16 June 2022

Price target decreased to CN¥27.73

Less than half of directors are independent

Investor sentiment improved over the past week

Consensus revenue estimates increase by 11%

Price target decreased to CN¥33.57

Price target decreased to CN¥33.57

Hualan Biological Engineering Inc., Annual General Meeting, Apr 28, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Hualan Biological Engineering Inc. Proposes Final Dividend for the Year 2021

Consensus revenue estimates fall by 32%

Price target decreased to CN¥36.80

Third quarter 2021 earnings released: EPS CN¥0.33 (vs CN¥0.25 in 3Q 2020)

Price target decreased to CN¥41.06

Investor sentiment deteriorated over the past week

Price target decreased to CN¥46.66

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day low: CN¥39.55

Hualan Biological Engineering Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day high: CN¥53.98

Investor sentiment improved over the past week

New 90-day low: CN¥42.50

New 90-day low: CN¥46.08

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations, earnings disappoint

Market pulls back on stock over the past week

Earnings released

New 90-day high - CN¥59.83

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin